The global idiopathic short stature drug market is anticipated to grow at a significant CAGR during the forecast period. Idiopathic short stature is defined as a condition in which the height of the individual is more than 2 standard deviations (SD) below the corresponding mean height for a given sex, age, and population, in whom no identifiable disorder persists. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay. The market growth is attributed to the growing awareness amongst people about various hormone related disorders and thus, the rising number of growth hormone options available. Further, the growing prevalence of several genetic disorders such as Turner syndrome, Prader-Willi syndrome, and Noonan syndrome are also likely to provide a boost to the demand for idiopathic short stature drugs. Generally, there is no specific disorder of growth hormone (GH)/ insulin-like growth factor (IGF) and any other endocrine disorder, however in rare cases, idiopathic short stature can be associated with their cause.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/idiopathic-short-stature-drug-market
Adding to this, the availability of insurance benefit in the developed economies such as the US further boosts the penetration of the biosimilar or biologics drugs used in the treatment of idiopathic short stature. While various treatment options are in the market majority of these are not approved for growth acceleration and hence, they are considered under off label use. Recombinant growth hormone therapy, Insulin like Growth Factor -1 (IGF-1) therapy, Aromatase inhibitors and low-dose androgen therapy (with injectable testosterone and low dose androgen) are some of the treatment options that have gain prominence in the past few years.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Product Type
o By Application
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Pfizer Inc., and Eli Lilly and Co., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Idiopathic Short Stature Drug Market Report by Segment
By Product
- BBT-031
- MMP-0201
- Somatropin
- Others
By Application
- Hospital
- Clinic
- Research Center
A full report of Idiopathic Short Stature Drug Market is available at: https://www.omrglobal.com/industry-reports/idiopathic-short-stature-drug-market
Idiopathic Short Stature Drug Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Pfizer Inc.
- Eli Lilly and Co.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
